Navidea Biopharmaceuticals Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Navidea Biopharmaceutica are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Navidea Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Navidea Biopharmaceutica is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 4.2 M |
Navidea |
Navidea Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest (100.00) in Navidea Biopharmaceuticals on April 23, 2025 and sell it today you would earn a total of 100.00 from holding Navidea Biopharmaceuticals or generate -100.0% return on investment over 90 days. Navidea Biopharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Navidea, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Navidea Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Navidea Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Navidea Biopharmaceuticals, and traders can use it to determine the average amount a Navidea Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NAVB |
Based on monthly moving average Navidea Biopharmaceutica is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Navidea Biopharmaceutica by adding Navidea Biopharmaceutica to a well-diversified portfolio.
Navidea Biopharmaceutica Fundamentals Growth
Navidea Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Navidea Biopharmaceutica, and Navidea Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Navidea Pink Sheet performance.
| Return On Equity | -11.0 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 3.5 M | ||||
| Shares Outstanding | 100.08 M | ||||
| Price To Earning | 0.53 X | ||||
| Price To Book | 8.16 X | ||||
| Price To Sales | 84.14 X | ||||
| Revenue | 65.65 K | ||||
| EBITDA | (14.05 M) | ||||
| Cash And Equivalents | 328.01 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 2.43 M | ||||
| Debt To Equity | 1.20 % | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (8.99 M) | ||||
| Earnings Per Share | (0.39) X | ||||
| Total Asset | 4.37 M | ||||
| Retained Earnings | (388 M) | ||||
| Current Asset | 12.58 M | ||||
| Current Liabilities | 6.18 M | ||||
Things to note about Navidea Biopharmaceutica performance evaluation
Checking the ongoing alerts about Navidea Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Navidea Biopharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Navidea Biopharmaceutica is not yet fully synchronised with the market data | |
| Navidea Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Navidea Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Navidea Biopharmaceuticals currently holds 2.43 M in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Navidea Biopharmaceutica has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Navidea Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Navidea Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Navidea Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Navidea to invest in growth at high rates of return. When we think about Navidea Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 65.65 K. Net Loss for the year was (15.18 M) with loss before overhead, payroll, taxes, and interest of (119.3 K). | |
| Navidea Biopharmaceuticals currently holds about 328.01 K in cash with (8.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 35.0% of Navidea Biopharmaceutica outstanding shares are owned by corporate insiders |
- Analyzing Navidea Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Navidea Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Navidea Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Navidea Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Navidea Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Navidea Biopharmaceutica's pink sheet. These opinions can provide insight into Navidea Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Navidea Pink Sheet
If you are still planning to invest in Navidea Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Navidea Biopharmaceutica's history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |